Oral therapy with apomorphine SL in erectile dysfunction;Orale therapie der erektilen dysfunktion mit apomorphin SL: Der erste zentrale initiator

Urologe - Ausgabe B

Volumn 41, Issue 4, 2001, Pages 372-378

  Altwein, J E ^a   Keuler, U ^a  

^a Urologische Abteilung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; SILDENAFIL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; ERECTILE DYSFUNCTION; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; PARKINSONISM; SUSTAINED RELEASE PREPARATION; TABLET;

EID: 0034849284     PISSN: 00421111     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001310170047     Document Type: Article

References (36)

1. Oral-medikamentöse therapie der erektilen dysfunktion: Grundlagen spektrum und grenzen
2. Physiology of penile erection
3. Neurophysiology of penile erection
4. Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat
5. Sildenafil citrate (viagra) in erectile dysfunction: Near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects
6. Efficacy and safety of apomorphine SL vs placebo for erectile dyfunction in patients with coronary artery disease
7. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine vs placebo in men with erectile dysfunction
8. Trazodone: A double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings
9. Impotence and its medical and psychological correlates: Results of MMAS
10. Die in neuester zeit in anwendung gekommenen arzneimittel. I. Apomorphium hydrochloratum
11. Absorption of apomorphine by various routes in parkinsonism
12. Oral sildenalfil in the treatment of erectile dysfunctio
13. Central control of erection and its pharmacological modification
14. Comparative results of goal oriented therapy for erectile dysfunction
15. Neural and pharmacological determinants of erection
16. Apomorphine: An update of clinical trial results
17. Recovery of erectile function by the oral administration of apomorphine
18. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: Implications for copulation
19. Incidence of erectile dysfunction in 40-69 years old: Longitudinal results from the MMAS
20. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects
21. Apomorphine-induced peníle tumescence in impotent patients - Preliminary findings
22. Sublingual apomorphin and Parkinson's disease
23. Efficacy of apomorphine SL vs. placebo for erectile dysfunction in patients with hypertension
24. Efficacy and safety of apomorphine SL vs. placebo for erectile dysfunction in patients with benign prostatic hyperplasia (BPH)
25. A D1 agonist in the MPOA facilitates copulation in male rats
26. The worldwide prevalence and epidemiology of erectile dysfunction
27. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus of male rats: Correlation with penile erection and yawning
28. EP 60761- and EP 50885-induced penile erection: Structure - Activity studies and comparision with apomorphine, oxytocin and N-methyl-D-aspartic acid
29. Efficacy and safety of fixed-dose, oral sildenafil in the treatment of erectile dysfunction of various etiologies
30. A brief male sexual function inventory for urology
31. Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction (MED)
32. Current perspectives on intracavernosal pharmacothreapy for erectile dysfunction
33. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction
34. Apomorphine in Parkinson's disease
35. Hypophysectomy prevents yawning and penile erection but not hypermotility induced by apomorphine
36. Diagnostic evaluation in the era of oral therapy